United States Federal Circuit
Janssen Pharm. N.V. v. Teva Pharm. USA, Inc., 08-1594
In a patent case involving a method for treating Alzheimer's disease and related dementias, district court's conclusion that the claims of the patent at issue were invalid is affirmed as the patent's description of using galantamine to treat the disease does not satisfy the enablement requirement because the patent application did not establish utility.
Appellate Information
- Decided 09/25/2009
- Published 09/25/2009
Judges
Court
- United States Federal Circuit